MYC inhibition in melanoma: Preclinical promise and the unveiling of a prognostic gene signature

Cutaneous melanoma, the most aggressive form of skin cancer, is the fifth most diagnosed cancer in Europe and one of the most frequent causes of cancer death, with incidence and mortality trends on the rise. While the development of more effective treatments including immune-based approaches have improved survival in some patients, many do not benefit from these anti-cancer therapies due to intrinsic or acquired drug resistance.